buprenorphin "actavis" 2 mg resoribletter, sublinguale
actavis group ptc ehf. - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg
buprenorphin "actavis" 8 mg resoribletter, sublinguale
actavis group ptc ehf. - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg
buprenorphine "orifarm" 2 mg resoribletter, sublinguale
orifarm generics a/s - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg
buprenorphine "orifarm" 8 mg resoribletter, sublinguale
orifarm generics a/s - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg
buprenorphine "teva" 2 mg resoribletter, sublinguale
teva b.v. - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg
buprenorphine "teva" 8 mg resoribletter, sublinguale
teva b.v. - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg
subutex 2 mg resoribletter, sublinguale
indivior europe limited - buprenorphinhydrochlorid - resoribletter, sublinguale - 2 mg
subutex 8 mg resoribletter, sublinguale
indivior europe limited - buprenorphinhydrochlorid - resoribletter, sublinguale - 8 mg
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
incivo
janssen-cilag international n.v. - telaprevir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - incivo, i kombination med peginterferon alfa og ribavirin, er indiceret til behandling af genotype-1 kronisk hepatitis c hos voksne patienter med kompenseret leversygdom (herunder skrumpelever):der er i behandling naive;som tidligere er blevet behandlet med interferon alfa (pegyleret eller non-pegyleret) alene eller i kombination med ribavirin, herunder relapsers, delvis respondenter og respondenter null.